LATEST NEWS: Sept 30, 2016 | BARDA Awards $51.9 Million Contract to DNAe to Develop Semiconductor DNA Sequencing Platform for Rapid Diagnosis of Antimicrobial Resistant Infections and Influenza

Bringing genomic diagnostics to the patient

DNA Electronics is a pioneer in genomic analysis, dedicated to applying our proven molecular diagnostic technology to bring real, life-saving benefits to patients. As the inventors of semiconductor sequencing (on-chip sequencing and analysis), we have created a new platform that is ideally suited to point-of-need diagnostics, by delivering actionable results direct from blood.

 

We call this Genalysis®.

 

Our first flagship product is a test that quickly identifies the microorganisms responsible for blood infections that may lead to sepsis. We are the first to build a purpose-designed genomic analysis platform to complete the entire diagnostic process, from raw sample input to clinically actionable output, within 2 to 3 hours.

Smart analysis

Genomic research has enabled a whole new wave of diagnostic testing based on DNA markers of diseases. Diseases characterized by small numbers of simple markers can be identified using relatively simple molecular diagnostic techniques such as real-time PCR, or genotyping. More complex conditions, involving multiple and/or complex markers require more comprehensive approaches such as Next Generation Sequencing (NGS).

 

However, current commercial NGS technology is still at the mainframe stage of evolution and firmly entrenched in the central research laboratory.

 

Genalysis® changes the rules of molecular diagnostics, by combining the best characteristics of PCR, genotyping and NGS on a single semiconductor chip that works directly at the point of need.

Live diagnostics

Fast tests save lives by allowing the most effective therapy to be identified and administered at the earliest stage of an infection. Appropriate treatment can begin swiftly, safeguarding the life of the patient and reducing the time spent in hospital.

Life-saving applications

Genalysis® testing will soon transform healthcare by providing lab-accurate diagnostics at the point of need. This has far-reaching and positive implications for personalized healthcare, infection screening and more. MORE

Managing infectious diseases

Our first product will diagnose bloodstream infections within 2 to 3 hours, identifying the infectious agent(s), so that the appropriate antibiotics can be given to the patient in time to stop any acceleration of the disease.   MORE

LATEST NEWS

 

 

Sept 30 2016

BARDA Awards $51.9 Million Contract to DNAe to Develop Semiconductor DNA Sequencing Platform for Rapid Diagnosis of Antimicrobial Resistant Infections and Influenza

MORE

 

 

Dec 4  2015

DNAe Expands US Operations with Clinical Diagnostic Development and Manufacturing Site in San Diego

MORE

 

 

Nov 2  2015

DNAe Secures £25 million ($38 million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections

MORE

 

 

MAY 27 2015

DNAe Chairman Professor Chris

Toumazou Awarded IEEE Field

Medal in Biomedical Engineering

for Outstanding Contributions

to Biomedical Circuit Technology

MORE

 

 

JAN 19 2015

DNAe Acquires nanoMR Inc. in a Strategic Move to Own Complete Workflow for Point-Of-Need NGS-Based Blood-To-Result Diagnostic

MORE

 

Company details

Email: contact@dnae.com

Switchboard: +44 (0)20 7036 2100

Fax: +44 (0)20 7036 2144

Twitter: @dna_electronics

 

 

© 2016 DNA Electronics

Find us

 

DNAe Group Holdings Ltd

Ugli Campus Block C

56 Wood Lane

London

W12 7SB

United Kingdom

 

Google map

 

Useful links

 

 

DNA Electronics, Inc.

1891 Rutherford Road

Suite 100

Carlsbad, CA 92008

USA

+1 (760) 444-9410

 

Google map

Designed and produced by Orchard